BioCentury
ARTICLE | Clinical News

Recomodulin: Phase III started

November 12, 2012 8:00 AM UTC

Asahi Kasei began a double-blind, placebo-controlled, international Phase III trial to evaluate 0.06 mg/kg IV ART-123 for up to 6 mg per day for 6 days in about 800 severe sepsis patients with coagulo...